A carregar...

Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance

SIMPLE SUMMARY: To ameliorate the situation for kidney cancer patients and to broaden the application of available drugs, we initiated this research to enhance the anti-cancer activity through combination treatment. There is an unmet need for innovative treatment strategies and optimized drug combin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Rausch, Magdalena, Weiss, Andrea, Zoetemelk, Marloes, Piersma, Sander R., Jimenez, Connie R., van Beijnum, Judy R., Nowak-Sliwinska, Patrycja
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7693411/
https://ncbi.nlm.nih.gov/pubmed/33126775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12113172
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!